Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Mutational landscape of adult xanthogranuloma

Blood (2025) 146 (Supplement 1): 7339.

https://doi.org/10.1182/blood-2025-7339

Published: 2025

Journal Articles

Evolving insights and changes in survival of erdheim-chester disease over time

Blood (2025) 146 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2025-2990

Published: 2025

Journal Articles

Efficacy of frontline fixed duration chemotherapy in MAPK-pathway altered adult langerhans cell histiocytosis: A multi-institutional international retrospective study

Blood (2025) 146 (Supplement 1): 2999.

https://doi.org/10.1182/blood-2025-2999

Published: 2025

Journal Articles

A phase I dose-finding study of mogamulizumab in combination with brentuximab vedotin in previously treated mycosis fungoides and Sézary syndrome

Lauren Shea, Lauren Hughey, Shantyle Kelly, Helen Obaro, Mayur Narkhede, Aditi Saha, Gaurav Goyal, Staci Shea, Heather Dillon, Paige Batson, Craig Elmets, Amitkumar Mehta

Blood (2025) 146 (Supplement 1): 7164.

https://doi.org/10.1182/blood-2025-7164

Published: 2025

Journal Articles

Clinical presentation and prognosis in erdheim-chester disease: Analysis of an international cohort of 1044 patients within the ecdga network

Blood (2025) 146 (Supplement 1): 192.

https://doi.org/10.1182/blood-2025-192

Published: 2025

Journal Articles

The molecular landscape of patients with malignant histiocytosis

Alanis Rodriguez-Rosario, Jithma Abeykoon, N. Nora Bennani, Karen Rech, Mithun Shah, Aishwarya Ravindran, Aldo Acosta Medina, Gordon Ruan, Dongni Yi, Saurabh Zanwar, Gaurav Goyal, Ronald Go

Blood (2025) 146 (Supplement 1): 7335.

https://doi.org/10.1182/blood-2025-7335

Published: 2025

Journal Articles

Discontinuation of targeted therapy in histiocytic neoplasms with durable response: A multicenter retrospective study

XI Yang, Haadi Ali, Dana Bossert, Carla Isabel Borre, Brinda H Shukla, Jacquelyn Fitzgerald, Mikaela McDonough, Corbin Wright, Fnu Amisha, Samuel Reynolds, Eric Jacobsen, Eli Diamond, Gaurav Goyal, Jithma Abeykoon, Ronald Go, Asra Ahmed

Blood (2025) 146 (Supplement 1): 726.

https://doi.org/10.1182/blood-2025-726

Published: 2025

Journal Articles

KRAS mutations in histiocytic neoplasms: Mutation spectrum and response to MEK inhibition

Blood (2025) 146 (Supplement 1): 6760.

https://doi.org/10.1182/blood-2025-6760

Published: 2025

Journal Articles

Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease

Gaurav Goyal, Anne S. Reiner, Dana Bossert, Allison M. Sigler, Mario E. Lacouture, Veronica Rotemberg, Jasmine H. Francis, Ronald S. Go, Raajit K. Rampal, Eli L. Diamond

Blood (2025) 145 (18): 2100–2103.

https://doi.org/10.1182/blood.2024028032

Published: 2025

Includes: Supplemental data

Journal Articles

High Prevalence of Concomitant Autoimmunity in Patients with Rosai-Dorfman Disease

Mitali Sen, Gordon J Ruan, Samuel B Reynolds, Haadi Ali, XI Yang, Diana Morlote, Aishwarya Ravindran, Lauren Kelly Shea, Matthew J Koster, Jithma P Abeykoon, Hind Salama, Xinxin Cao, Asra Z. Ahmed, Ronald S Go, Gaurav Goyal

Blood (2024) 144 (Supplement 1): 3910.

https://doi.org/10.1182/blood-2024-201817

Published: 2024

Journal Articles

Efficacy of Small Molecule Kinase Inhibitors in Histiocytic Neoplasms with Non-BRAFV600E Mutations: Concordance of Pre-Clinical Predictions to Clinical Responses

Alanis Enid Rodriguez-Rosario, Aldo Adrian Acosta Medina, N. Nora Bennani, Gaurav Goyal, Aishwarya Ravindran, Karen L Rech, Gordon J Ruan, Mithun V Shah, Dongni Yi, Saurabh Zanwar, Jithma P Abeykoon, Ronald S Go

Blood (2024) 144 (Supplement 1): 4564.

https://doi.org/10.1182/blood-2024-205474

Published: 2024

Journal Articles

Efficacy of Targeted Agents and Immune Checkpoint Inhibitors in Patients with Malignant Histiocytosis

Blood (2024) 144 (Supplement 1): 4563.

https://doi.org/10.1182/blood-2024-204398

Published: 2024

Journal Articles

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 570.

https://doi.org/10.1182/blood-2024-199845

Published: 2024

Journal Articles

Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Adi Zoref-Lorenz, Elliot J Cahn, Eric Mou, Yucai Wang, Matthew J. Maurer, Andrew L. Feldman, Bri J Negaard, Raphael Mwangi, Gilad Itchaki, Grzegorz S. Nowakowski, Thomas M. Habermann, Brian K. Link, Stephen M. Ansell, Anne J. Novak, Gaurav Goyal, Thomas E. Witzig, James R. Cerhan, Michael B. Jordan

Blood (2024) 144 (Supplement 1): 1624.

https://doi.org/10.1182/blood-2024-210119

Published: 2024

Journal Articles

Subclassification of Erdheim-Chester Disease: Distinct Clinical and Molecular Findings between Classical and Non-Classical Forms

Blood (2024) 144 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2024-193841

Published: 2024

Journal Articles

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

Mayur S. Narkhede, Antonio Di Stasi, Lauren Kelly Shea, Susan Bal, Gayathri Ravi, Gaurav Goyal, Pamela Hardwick, Smith Giri, Donna Salzman, Ravi Bhatia, Luciano J. Costa, Amitkumar Mehta

Blood (2024) 144 (Supplement 1): 3449.

https://doi.org/10.1182/blood-2024-205205

Published: 2024

Journal Articles

ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Blood (2024) 144 (Supplement 1): 805.

https://doi.org/10.1182/blood-2024-204230

Published: 2024

Journal Articles

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 459.

https://doi.org/10.1182/blood-2024-204113

Published: 2024

Journal Articles

BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis

Blood (2023) 142 (18): 1570–1575.

https://doi.org/10.1182/blood.2023021212

Published: 2023

Includes: Supplemental data

Journal Articles

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Blood (2023) 142 (Supplement 1): 308.

https://doi.org/10.1182/blood-2023-183001

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Mutational landscape of adult xanthogranuloma

Evolving insights and changes in survival of erdheim-chester disease over time

Efficacy of frontline fixed duration chemotherapy in MAPK-pathway altered adult langerhans cell histiocytosis: A multi-institutional international retrospective study

A phase I dose-finding study of mogamulizumab in combination with brentuximab vedotin in previously treated mycosis fungoides and Sézary syndrome

Clinical presentation and prognosis in erdheim-chester disease: Analysis of an international cohort of 1044 patients within the ecdga network

The molecular landscape of patients with malignant histiocytosis

Discontinuation of targeted therapy in histiocytic neoplasms with durable response: A multicenter retrospective study

KRAS mutations in histiocytic neoplasms: Mutation spectrum and response to MEK inhibition

Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease

High Prevalence of Concomitant Autoimmunity in Patients with Rosai-Dorfman Disease

Efficacy of Small Molecule Kinase Inhibitors in Histiocytic Neoplasms with Non-BRAFV600E Mutations: Concordance of Pre-Clinical Predictions to Clinical Responses

Efficacy of Targeted Agents and Immune Checkpoint Inhibitors in Patients with Malignant Histiocytosis

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Subclassification of Erdheim-Chester Disease: Distinct Clinical and Molecular Findings between Classical and Non-Classical Forms

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only